Combined administration of inhaled DNase, baricitinib and tocilizumab as rescue treatment in COVID-19 patients with severe respiratory failure

Combined administration of inhaled DNase, baricitinib and tocilizumab as rescue treatment in COVID-19 patients with severe respiratory failure

Aiming to reduce mortality in COVID-19 with severe respiratory failure we administered a combined rescue treatment (COMBI) on top of standard-of-care (SOC: dexamethasone/heparin) consisted of inhaled DNase to dissolve thrombogenic neutrophil extracellular traps, plus agents against cytokine-mediated...

Full description

Bibliographic Details
Main Authors: Antoniadou, C. (Author), Bakola, S.-A (Author), Chrysanthopoulou, A. (Author), Fotiadou, I. (Author), Gavriilidis, E. (Author), Kogias, D. (Author), Mikroulis, D. (Author), Mitroulis, I. (Author), Natsi, A.-M (Author), Ntinopoulou, M. (Author), Papadopoulos, V. (Author), Papagoras, C. (Author), Peichamperis, P. (Author), Pelekoudas, C. (Author), Ritis, K. (Author), Satiridou, E. (Author), Skendros, P. (Author), Smyrlis, A. (Author), Zioga, N. (Author)
Format: Article
Language:English
Published: Academic Press Inc. 2022
Subjects:
Baricitinib
COVID-19
DNase
Fibroblasts
Tissue factor
Tocilizumab
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items